Furthermore, SALL4 was highly expressed in tamoxifen-resistant (TAMR) patients and had a positive correlation with Oct4, Nanog, and SOX2 stemness markers, suggesting that SALL4 overexpression contributed to TAMR and poor survival rates in tamoxifen-treated BC patients [154]. Here, SALL4 is linked to breast cancer.